|
BPAX, MDCE, KERX, QTEK, NNAN, GEAR
Our Stocks to Watch today include BioSante Pharmaceuticals Inc. (NASDAQ: BPAX), Medical Care Technologies Inc. (OTCBB: MDCE), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Quintek Technologies Inc. (OTC: QTEK), NaturalNano Inc. (OTCBB: NNAN) and Gear International Inc. (OTC: GEAR).
BIOSANTE PHARMACEUTICALS INCORPORATED (NASDAQ: BPAX)
"Up 24.93% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BPAX.php
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at www.biosantepharma.com.
BPAX News:
May 8 - BioSante Pharmaceuticals Reports First Quarter Financial Results
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reported on its financial results for the first quarter of 2012 and cash balance as of March 31, 2012.
BioSante’s cash balance as of March 31, 2012 was approximately $49.5 million, compared to a cash balance of approximately $57.3 million on December 31, 2011.
BioSante incurred a net loss of approximately $10.3 million or $(0.09) per share for the quarter ended March 31, 2012, compared to a net loss of $17.3 million or $(0.20) per share for the same period in 2011. The decrease in the net loss was due primarily to lower expenses associated with the clinical development of LibiGel® (testosterone gel).
BioSante’s corporate strategy always has included product development of high value medically-needed pharmaceutical products. In light of the top-line results from the two pivotal LibiGel Phase III efficacy trials, which indicated that LibiGel did not meet its co-primary or secondary endpoints, management continues to assess LibiGel’s path forward and potential alternative strategies to utilize the continuing LibiGel Phase III cardiovascular events and breast cancer safety study. Management also has expanded efforts to explore new product development projects through in-licensing and mergers and acquisitions as well as to develop further the GVAX cancer vaccine portfolio.
The current projected cash burn rate for 2012 is approximately $2.5 million per month, including expenditures related to the ongoing LibiGel safety study. If a decision is made to halt the LibiGel safety study, the monthly cash burn rate will decline to approximately $1.5 million per month, pending other product development and corporate activities.
MEDICAL CARE TECHNOLOGIES INCORPORATED (OTCBB: MDCE)
"Up 28.57% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/MDCE.php
Medical Care Technologies Inc. is traded under the symbol "MDCE" on the OTCBB and is headquartered in Beijing, China. MDCE, through joint ventures or Chinese subsidiaries, develops a network of children's health facilities in the larger urban areas throughout China. Services are geared towards the advancing economic middle-class and upper class Chinese families. Specializing in the care of children between the ages of 3 to 16, MDCE's role is to enhance the overall well-being of the family and community and to expand its pediatric services to include preventative health and wellness education. MDCE, through its children's health facilities, will also distribute a diverse range of industry-leading pharmaceutical and nutraceutical product lines. MDCE's main mission is simple – to become a healthcare service provider leader in children's health.
MDCE News:
April 30 - Medical Care Technologies Inc. Receives $10 Million Reserve Equity Financing From AGS Capital Group, LLC
Medical Care Technologies Inc. (OTCBB: MDCE), a growing children's healthcare service provider, is extremely pleased to announce that it has received a Reserve Equity Financing of US$10,000,000 over a term of 4 years.
The Reserve Equity Financing ("REF") with AGS Capital Group, LLC, is a comprehensive financing solution that will provide direct investment capital of up to $10 million without putting undue stress upon the Company's share capital structure. It is an inexpensive and flexible financing strategy in which the Company controls the amount of any advance and its timing – the how and when, therefore, regulating and minimizing any potential impairment to its share structure.
"We believe this funding will provide us with the flexibility needed to expand our business," said Luis Kuo, Chief Operating Officer. "As the demand in China to implement our business model and to expand our children's health centers to other locations has been overwhelming, securing the right financing will give us the ability to manage both the long-term growth of the Company and shareholder value."
Ning Wu, Chief Executive Officer, stated, "We are excited to be entering into a relationship with a strong financial partner. It took research and many months to come to what we believe will turn the tides for Medical Care Technologies Inc. This type of financing will allow us to grow, concentrating our efforts on developing, building and staffing of children's health centers without the constant pressure of financing."
"We believe that there is a tremendous market in China for the services that Medical Care Technologies Inc. provides and see significant growth for the company during the next year," says Allen Silberstein, Chief Investment Officer of AGS Capital Group.
ABOUT AGS CAPITAL GROUP, LLC
AGS Capital Group provides flexible equity financing solutions for growth-stage and mid cap public companies as well as private companies looking to go public. AGS Capital Group invests in public companies around the world listed on most exchanges. AGS Capital Group performs fundamental analysis including credit risk, technical analysis of market trends and industry, evaluation of management team experience and corporate structure evaluation.
KERYX BIOPHARMACEUTICALS INCORPORATED (NASDAQ: KERX)
"Up 17.53% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/KERX.php
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease and cancer. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing KRX-0401 (perifosine), which is in Phase 3 clinical development for multiple myeloma. Keryx is headquartered in New York City.
KERX News:
May 21 - Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) announced that an abstract highlighting the dose related increases in iron storage parameters as observed in prior clinical trials of Zerenex™ (ferric citrate), has been accepted for poster presentation at the upcoming 49th ERA-EDTA (European Renal Association – European Dialysis and Transplant Association) Congress, taking place May 24-27, 2012, in Paris, France.
The following poster will be presented on Saturday, May 26, 2012, from 9:30am to 10:45am local time:
* A Meta-Analysis of Ferric Citrate for Hyperphosphatemia: The Effects of an Oral Iron-Containing Phosphate Binder on Serum Ferritin and Saturated Transferrin in Hemodialysis Patients (Abstract # SAP534)
Zerenex, the Company's oral, ferric iron-based drug candidate for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis, is currently in Phase 3 clinical development pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. The Zerenex Phase 3 registration program is comprised of an already completed Phase 3 short-term study, and an ongoing Phase 3 long-term study.
Keryx holds a worldwide license (except for certain Asian Pacific countries) to Zerenex (ferric citrate) from Panion & BF Biotech, Inc. The Japanese rights are sublicensed by Keryx to Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.
QUINTEK TECHNOLOGIES INCORPORATED (OTC: QTEK)
"Up 21.74% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/QTEK.php
Quintek Technologies, Inc., together with its subsidiaries, provides back office services and solutions to organizations principally in the United States. It offers back office services and solutions through out-sourcing/in-sourcing services, consulting services, and solution sales. The company’s business process include business records storage and management consulting services ranging from consulting, digitizing, indexing, and uploading of source documents; disaster recovery / business continuity solutions, which provide availability and remote disaster recovery of Microsoft Exchange, as well as enable companies to deploy email continuity by protecting mission -critical Microsoft Exchange Servers; and document destruction services, including the destruction of confidential records. Quintek also sells hardware, software, and services for chemical-free desktop microfilm printer used in printing aperture cars from electronic files used for document management and archival storage. The company was founded in 1991 and is headquartered in Huntington Beach, California.
QTEK News:
No recent news for Quintek Technologies, Inc. (OTC: QTEK).
NATURALNANO INCORPORATED (OTCBB: NNAN)
"Up 25.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/NNAN.php
NaturalNano, Inc. is a materials science company focused on developing and commercializing advanced nanocomposites. The Company is focused on additive technologies and processes, including its proprietary Pleximer that adds value to industrial polymers, plastics and composites. NaturalNano holds and/or licenses 20 patents and applications relating to Halloysite, as well as proprietary know-how for its extraction and separation processes, compositions, and derivatives.
NNAN News:
May 11 - NaturalNano Retains Park Avenue Investor Relations as Public and Investor Relations Advisor
NaturalNano, Inc. (OTCBB: NNAN) announced that it has retained the firm of Park Avenue Investor Relations based in Rochester, NY to provide investor relations (IR) services to NaturalNano. Park Avenue IR was founded by top-ranked analyst and IR executive Tom Morabito and provides a full range of investor services including investor outreach and targeting, financial results and media support.
NaturalNano's CEO James Wemett commented, "We are excited to announce our relationship with Park Avenue IR. Tom Morabito has nearly 20 years of investor relations, finance, and capital markets experience. We believe that he and his team will be a tremendous resource for NaturalNano as our business continues to expand. Park Avenue IR has the skill and experience to get our exciting story out to a broader group of investors."
GOLFGEAR INTERNATIONAL INCORPORATED (OTC: GEAR)
"Up 63.79% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/GEAR.php
GolfGear International, Inc. was originally incorporated in 1996 as a golf equipment company. The Company has recently altered its business strategy to include gold and silver mining, providing financing for gold and silver mining projects, and precious metals processing and refining.
GEAR News:
May 20 - Gear International, Inc. Updates Financial Statements, Shows Increased Value and Progress of Business Model
Gear International, Inc. (OTC: GEAR) released financial statements demonstrating significant improvement in asset value and cash on balance from 2010 to the current fiscal year. Complemented by a series of asset acquisitions and joint venture agreements on several mining claims, the underlying company financials suggest a fundamental enhancement of shareholder value could soon be realized. GEAR has added 5 mining claims and improved its cash reserves. Additionally, GEAR management is anticipating a market correction in the value of the company's stock after successfully eliminating a hostile shareholder from the float.
GEAR's value to its stockholders continues to exhibit transformational potential. During the period between December 31st 2010 and December 31st 2011, GEAR's stockholder equity transformed from a negative value to over 7 million dollars with minimal public activity or wealth generating capacity. In 2012, management's substantial improved GEAR's brand awareness, activities, and asset claims.
GEAR president Dale Geck affirms: "The industry averages for mining companies possessing producing assets suggest that current and near term shareholders could be observing exponentially increased value within the next few quarters. Company due diligence was unable to yield evidence of a publicly traded company with ownership of a producing gold mine maintaining market capitalization of less than 500 million USD; GEAR has several projects with historical reserve volumes exceeding that number. Over the next 120 days as we register those reserves with today's leading standards, current shareholder values could be rendered obsolete."
|
